

## Perioperative Management of Anticoagulant Therapy

(2023-2026)

### REFERENCES

1. Precht C, Demirel Y, Assaf AT, et al. Perioperative Management in Patients With Undergoing Direct Oral Anticoagulant Therapy in Oral Surgery - A Multicentric Questionnaire Survey. *In Vivo*. 2019;33(3):855-862. doi:10.21873/invivo.11550
2. Chahine J, Khoudary MN, Nasr S. Anticoagulation Use prior to Common Dental Procedures: A Systematic Review. *Cardiol Res Pract*. 2019;2019:9308631. Published 2019 Jun 2. doi:10.1155/2019/9308631
3. Douketis JD, Spyropoulos AC, Murad MH, et al. Perioperative Management of Antithrombotic Therapy: An American College of Chest Physicians Clinical Practice Guideline [published correction appears in *Chest*. 2023 Jul;164(1):267]. *Chest*. 2022;162(5):e207-e243. doi:10.1016/j.chest.2022.07.025
4. Doherty JU, Gluckman TJ, Hucker WJ, et al. 2017 ACC Expert Consensus Decision Pathway for Periprocedural Management of Anticoagulation in Patients With Nonvalvular Atrial Fibrillation: A Report of the American College of Cardiology Clinical Expert Consensus Document Task Force. *J Am Coll Cardiol*. 2017;69(7):871-898. doi:10.1016/j.jacc.2016.11.024
5. Tafur AJ, Clark NP, Spyropoulos AC, et al. Predictors of Bleeding in the Perioperative Anticoagulant Use for Surgery Evaluation Study. *J Am Heart Assoc*. 2020;9(19):e017316. doi:10.1161/JAHA.120.017316
6. Clark NP, Douketis JD, Hasselblad V, et al. Predictors of perioperative major bleeding in patients who interrupt warfarin for an elective surgery or procedure: Analysis of the BRIDGE trial. *Am Heart J*. 2018;195:108-114. doi:10.1016/j.ahj.2017.09.015
7. Spyropoulos AC, Turpie AG, Dunn AS, et al. Perioperative bridging therapy with unfractionated heparin or low-molecular-weight heparin in patients with mechanical prosthetic heart valves on long-term oral anticoagulants (from the REGIMEN Registry). *Am J Cardiol*. 2008;102(7):883-889. doi:10.1016/j.amjcard.2008.05.042
8. Nishimura RA, Otto CM, Bonow RO, et al. 2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *Circulation*. 2017;135(25):e1159-e1195. doi:10.1161/CIR.0000000000000503
9. Thrombosis Canada. [www.ThrombosisCanada.ca](http://www.ThrombosisCanada.ca). Accessed September 12, 2022. <http://www.thrombosiscanada.ca>

10. Nazha B, Pandya B, Cohen J, et al. Periprocedural Outcomes of Direct Oral Anticoagulants Versus Warfarin in Nonvalvular Atrial Fibrillation. *Circulation*. 2018;138(14):1402-1411. doi:10.1161/CIRCULATIONAHA.117.031457
11. University of Washington Medical Center Anticoagulation Clinics. Suggestions for anticoagulation management before and after dental procedures. Available at: <https://sites.uw.edu/anticoag/conditions/peri-procedural-anticoagulation/suggestions-for-anticoagulation-management-before-and-after-dental-procedures/>. Accessed September 4, 2019.
12. Nematullah A, Alabousi A, Blanas N, Douketis JD, Sutherland SE. Dental surgery for patients on anticoagulant therapy with warfarin: a systematic review and meta-analysis. *J Can Dent Assoc*. 2009;75(1):41.
13. Patatanian E, Fugate SE. Hemostatic mouthwashes in anticoagulated patients undergoing dental extraction. *Ann Pharmacother*. 2006;40(12):2205-2210. doi:10.1345/aph.1H295
14. Jeske AH, Suchko GD; ADA Council on Scientific Affairs and Division of Science; Journal of the American Dental Association. Lack of a scientific basis for routine discontinuation of oral anticoagulation therapy before dental treatment [published correction appears in *J Am Dent Assoc*. 2004 Jan;135(1):28]. *J Am Dent Assoc*. 2003;134(11):1492-1497. doi:10.14219/jada.archive.2003.0080
15. Jamula E, Anderson J, Douketis JD. Safety of continuing warfarin therapy during cataract surgery: a systematic review and meta-analysis. *Thromb Res*. 2009;124(3):292-299. doi:10.1016/j.thromres.2009.01.007
16. Wahl MJ. Myths of dental surgery in patients receiving anticoagulant therapy. *J Am Dent Assoc*. 2000;131(1):77-81. doi:10.14219/jada.archive.2000.0024
17. Takeuchi Y, Mabe K, Shimodate Y, et al. Continuous Anticoagulation and Cold Snare Polypectomy Versus Heparin Bridging and Hot Snare Polypectomy in Patients on Anticoagulants With Subcentimeter Polyps: A Randomized Controlled Trial. *Ann Intern Med*. 2019;171(4):229-237. doi:10.7326/M19-0026
18. Abraham NS, Barkun AN, Sauer BG, et al. American College of Gastroenterology-Canadian Association of Gastroenterology Clinical Practice Guideline: Management of Anticoagulants and Antiplatelets During Acute Gastrointestinal Bleeding and the Periendoscopic Period. *J Can Assoc Gastroenterol*. 2022;5(2):100-101. Published 2022 Mar 17. doi:10.1093/jcag/gwac010
19. Eisen GM, Baron TH, Dominitz JA, et al. Guideline on the management of anticoagulation and antiplatelet therapy for endoscopic procedures. *Gastrointest Endosc*. 2002;55(7):775-779. doi:10.1016/s0016-5107(02)70402-1
20. Birnie DH, Healey JS, Wells GA, et al. Pacemaker or defibrillator surgery without interruption of anticoagulation. *N Engl J Med*. 2013;368(22):2084-2093. doi:10.1056/NEJMoa1302946

21. Ghanbari H, Phard WS, Al-Ameri H, et al. Meta-analysis of safety and efficacy of uninterrupted warfarin compared to heparin-based bridging therapy during implantation of cardiac rhythm devices. *Am J Cardiol.* 2012;110(10):1482-1488. doi:10.1016/j.amjcard.2012.06.057
22. Lip GYH, Banerjee A, Boriani G, et al. Antithrombotic Therapy for Atrial Fibrillation: CHEST Guideline and Expert Panel Report. *Chest.* 2018;154(5):1121-1201. doi:10.1016/j.chest.2018.07.040
23. Lazio BE, Simard JM. Anticoagulation in neurosurgical patients. *Neurosurgery.* 1999;45(4):838-848. doi:10.1097/00006123-199910000-00022
24. Douketis JD. Perioperative anticoagulation management in patients who are receiving oral anticoagulant therapy: a practical guide for clinicians. *Thromb Res.* 2002;108(1):3-13. doi:10.1016/s0049-3848(02)00387-0
25. Eijgenraam P, ten Cate H, ten Cate-Hoek AJ. Practice of bridging anticoagulation: guideline adherence and risk factors for bleeding. *Neth J Med.* 2014;72(3):157-164.
26. Bell BR, Spyropoulos AC, Douketis JD. Perioperative Management of the Direct Oral Anticoagulants: A Case-Based Review. *Hematol Oncol Clin North Am.* 2016;30(5):1073-1084. doi:10.1016/j.hoc.2016.05.005
27. Horlocker TT, Vandermeulen E, Kopp SL, Gogarten W, Leffert LR, Benzon HT. Regional Anesthesia in the Patient Receiving Antithrombotic or Thrombolytic Therapy: American Society of Regional Anesthesia and Pain Medicine Evidence-Based Guidelines (Fourth Edition) [published correction appears in *Reg Anesth Pain Med.* 2018 Jul;43(5):566. Vandermeulen, Erik [corrected to Vandermeulen, Erik]]. *Reg Anesth Pain Med.* 2018;43(3):263-309. doi:10.1097/AAP.0000000000000763
28. Hylek EM, Regan S, Go AS, Hughes RA, Singer DE, Skates SJ. Clinical predictors of prolonged delay in return of the international normalized ratio to within the therapeutic range after excessive anticoagulation with warfarin. *Ann Intern Med.* 2001;135(6):393-400. doi:10.7326/0003-4819-135-6-200109180-00008
29. Kamali F, Wynne H. Pharmacogenetics of warfarin. *Annu Rev Med.* 2010;61:63-75. doi:10.1146/annurev.med.070808.170037
30. Woods K, Douketis JD, Kathirgamanathan K, Yi Q, Crowther MA. Low-dose oral vitamin K to normalize the international normalized ratio prior to surgery in patients who require temporary interruption of warfarin. *J Thromb Thrombolysis.* 2007;24(2):93-97. doi:10.1007/s11239-007-0022-z
31. Shields RC, McBane RD, Kuiper JD, Li H, Heit JA. Efficacy and safety of intravenous phytonadione (vitamin K1) in patients on long-term oral anticoagulant therapy. *Mayo Clin Proc.* 2001;76(3):260-266. doi:10.4065/76.3.260
32. Spyropoulos AC, Al-Badri A, Sherwood MW, Douketis JD. Perioperative management of patients receiving a vitamin K antagonist or a direct oral anticoagulant requiring an elective procedure or surgery. *J Thromb Haemost.* 2016;14(5):875-885. doi:10.1111/jth.13305

33. Siegal D, Yudin J, Kaatz S, Douketis JD, Lim W, Spyropoulos AC. Periprocedural heparin bridging in patients receiving vitamin K antagonists: systematic review and meta-analysis of bleeding and thromboembolic rates. *Circulation*. 2012;126(13):1630-1639. doi:10.1161/CIRCULATIONAHA.112.105221
34. Kovacs MJ, Wells PS, Anderson DR, et al. Postoperative low molecular weight heparin bridging treatment for patients at high risk of arterial thromboembolism (PERIOP2): double blind randomised controlled trial. *BMJ*. 2021;373:n1205. Published 2021 Jun 9. doi:10.1136/bmj.n1205
35. Steinberg BA, Peterson ED, Kim S, et al. Use and outcomes associated with bridging during anticoagulation interruptions in patients with atrial fibrillation: findings from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). *Circulation*. 2015;131(5):488-494. doi:10.1161/CIRCULATIONAHA.114.011777
36. Douketis JD, Spyropoulos AC, Kaatz S, et al. Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation. *N Engl J Med*. 2015;373(9):823-833. doi:10.1056/NEJMoa1501035
37. Douketis JD, Healey JS, Brueckmann M, et al. Perioperative bridging anticoagulation during dabigatran or warfarin interruption among patients who had an elective surgery or procedure. Substudy of the RE-LY trial. *Thromb Haemost*. 2015;113(3):625-632. doi:10.1160/TH14-04-0305
38. Clark NP, Witt DM, Davies LE, et al. Bleeding, Recurrent Venous Thromboembolism, and Mortality Risks During Warfarin Interruption for Invasive Procedures. *JAMA Intern Med*. 2015;175(7):1163-1168. doi:10.1001/jamainternmed.2015.1843
39. Ayoub K, Nairooz R, Almomani A, Marji M, Paydak H, Maskoun W. Perioperative Heparin Bridging in Atrial Fibrillation Patients Requiring Temporary Interruption of Anticoagulation: Evidence from Meta-analysis. *J Stroke Cerebrovasc Dis*. 2016;25(9):2215-2221. doi:10.1016/j.jstrokecerebrovasdis.2016.04.006
40. Martel N, Lee J, Wells PS. Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis. *Blood*. 2005;106(8):2710-2715. doi:10.1182/blood-2005-04-1546
41. Enoxaparin [package insert]. Bridgewater, NJ: Sanofi-Aventis; 2007.
42. Dalteparin [package insert]. New York, NY: Pfizer Inc; 2007.
43. Tinzaparin [package insert]. Ballerup, Denmark: Leo Pharmaceutical Products; 2008.
44. Barras MA, Duffull SB, Atherton JJ, Green B. Individualized dosing of enoxaparin for subjects with renal impairment is superior to conventional dosing at achieving therapeutic concentrations. *Ther Drug Monit*. 2010;32(4):482-488. doi:10.1097/FTD.0b013e3181e64846
45. O'Donnell MJ, Kearon C, Johnson J, et al. Brief communication: Preoperative anticoagulant activity after bridging low-molecular-weight heparin for temporary interruption of warfarin. *Ann Intern Med*. 2007;146(3):184-187. doi:10.7326/0003-4819-146-3-200702060-00007
46. Katholi RE, Nolan SP, McGuire LB. Living with prosthetic heart valves. Subsequent noncardiac operations and the risk of thromboembolism or hemorrhage. *Am Heart J*. 1976;92(2):162-167. doi:10.1016/s0002-8703(76)80251-7

47. Katholi RE, Nolan SP, McGuire LB. The management of anticoagulation during noncardiac operations in patients with prosthetic heart valves. A prospective study. *Am Heart J*. 1978;96(2):163-165. doi:10.1016/0002-8703(78)90080-7
48. Healey JS, Eikelboom J, Douketis J, et al. Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) randomized trial [published correction appears in *Circulation*. 2012 Sep 4;126(10):e160. Heidbuchle, Hein [corrected to Heidbuchel, Hein]]. *Circulation*. 2012;126(3):343-348. doi:10.1161/CIRCULATIONAHA.111.090464
49. Spyropoulos AC, Douketis JD. How I treat anticoagulated patients undergoing an elective procedure or surgery. *Blood*. 2012;120(15):2954-2962. doi:10.1182/blood-2012-06-415943
50. Siegal D. "Stop In the Name of Blood: Perioperative Anticoagulation", SHM 2022 Presentation.
51. Barnes GD, Ageno W, Ansell J, Kaatz S; Subcommittee on the Control of Anticoagulation of the International Society on Thrombosis and Haemostasis. Recommendation on the nomenclature for oral anticoagulants: communication from the SSC of the ISTH [published correction appears in *J Thromb Haemost*. 2015 Aug;13(8):1539]. *J Thromb Haemost*. 2015;13(6):1154-1156. doi:10.1111/jth.12969
52. Sié P, Samama CM, Godier A, et al. Surgery and invasive procedures in patients on long-term treatment with direct oral anticoagulants: thrombin or factor-Xa inhibitors. Recommendations of the Working Group on Perioperative Haemostasis and the French Study Group on Thrombosis and Haemostasis. *Arch Cardiovasc Dis*. 2011;104(12):669-676. doi:10.1016/j.acvd.2011.09.001
53. Xarelto (rivaroxaban) package insert. 2011; <https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/XARELTO-pi.pdf>. Accessed Nov 11, 2022.
54. Pradaxa (dabigatran) package insert. 2010; <https://content.boehringer-ingenheim.com/DAM/c669f898-0c4e-45a2-ba55-af1e011fdf63/pradaxa%20capsules-us-pi.pdf>. Accessed Nov 11, 2022
55. Eliquis (apixaban) package insert. 2012; [https://packageinserts.bms.com/pi/pi\\_eliquis.pdf](https://packageinserts.bms.com/pi/pi_eliquis.pdf). Accessed Nov 11, 2022.
56. Savaysa (edoxaban) package insert. 2015; [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2015/206316lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206316lbl.pdf). Accessed Nov 11, 2022.
57. Arixtra (fondaparinux) package insert. 2001; [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2005/021345s010lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/021345s010lbl.pdf). Accessed Nov 11, 2022.
58. Schulman S, Carrier M, Lee AY, et al. Perioperative Management of Dabigatran: A Prospective Cohort Study. *Circulation*. 2015;132(3):167-173. doi:10.1161/CIRCULATIONAHA.115.015688

59. Douketis JD, Wang G, Chan N, et al. Effect of standardized perioperative dabigatran interruption on the residual anticoagulation effect at the time of surgery or procedure. *J Thromb Haemost.* 2016;14(1):89-97. doi:10.1111/jth.13178
60. Douketis JD, Syed S, Schulman S. Periprocedural Management of Direct Oral Anticoagulants: Comment on the 2015 American Society of Regional Anesthesia and Pain Medicine Guidelines. *Reg Anesth Pain Med.* 2016;41(2):127-129. doi:10.1097/AAP.0000000000000360
61. Shaw JR, Douketis J, Le Gal G, Carrier M. Periprocedural interruption of anticoagulation in patients with cancer-associated venous thromboembolism: An analysis of thrombotic and bleeding outcomes. *J Thromb Haemost.* 2019;17(7):1171-1178. doi:10.1111/jth.14468
62. Samuelson BT, Cuker A, Siegal DM, Crowther M, Garcia DA. Laboratory Assessment of the Anticoagulant Activity of Direct Oral Anticoagulants: A Systematic Review. *Chest.* 2017;151(1):127-138. doi:10.1016/j.chest.2016.08.1462
63. No author listed. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials [published correction appears in *Arch Intern Med* 1994 Oct 10;154(19):2254]. *Arch Intern Med.* 1994;154(13):1449-1457.
64. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. *Stroke.* 1991;22(8):983-988. doi:10.1161/01.str.22.8.983
65. Cardiogenic brain embolism. The second report of the Cerebral Embolism Task Force [published correction appears in *Arch Neurol* 1989 Oct;46(10):1079]. *Arch Neurol.* 1989;46(7):727-743.
66. Sherman DG, Hart RG, Easton JD. The secondary prevention of stroke in patients with atrial fibrillation. *Arch Neurol.* 1986;43(1):68-70. doi:10.1001/archneur.1986.00520010062024
67. van Latum JC, Koudstaal PJ, Venables GS, van Gijn J, Kappelle LJ, Algra A. Predictors of major vascular events in patients with a transient ischemic attack or minor ischemic stroke and with nonrheumatic atrial fibrillation. European Atrial Fibrillation Trial (EAFT) Study Group. *Stroke.* 1995;26(5):801-806. doi:10.1161/01.str.26.5.801
68. Friberg, L., Rosenqvist, M., & Lip, G. Y. (2012). Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study. *European heart journal*, 33(12), 1500–1510. <https://doi.org/10.1093/eurheartj/ehr488>
69. Gage BF, Waterman AD, Shannon W, Boehler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. *JAMA.* 2001;285(22):2864-2870. doi:10.1001/jama.285.22.2864
70. McAlister FA, Jacka M, Graham M, et al. The prediction of postoperative stroke or death in patients with preoperative atrial fibrillation undergoing non-cardiac surgery: a VISION sub-study. *J Thromb Haemost.* 2015;13(10):1768-1775. doi:10.1111/jth.13110
71. Essebag V, Proietti R, Birnie DH, et al. Short-term dabigatran interruption before cardiac rhythm device implantation: multi-centre experience from the RE-LY trial. *Europace.* 2017;19(10):1630-1636. doi:10.1093/europace/euw409

72. Spyropoulos AC, Turpie AG, Dunn AS, et al. Clinical outcomes with unfractionated heparin or low-molecular-weight heparin as bridging therapy in patients on long-term oral anticoagulants: the REGIMEN registry. *J Thromb Haemost*. 2006;4(6):1246-1252. doi:10.1111/j.1538-7836.2006.01908.x
73. John A. Heit, Alexander T. Cohen, Frederick A. Anderson, on Behalf of the VTE Impact Assessment Group; Estimated Annual Number of Incident and Recurrent, Non-Fatal and Fatal Venous Thromboembolism (VTE) Events in the US.. *Blood* 2005; 106 (11): 910. doi: <https://doi.org/10.1182/blood.V106.11.910.910>
74. Deitelzweig SB, Johnson BH, Lin J, Schulman KL. Prevalence of clinical venous thromboembolism in the USA: current trends and future projections. *Am J Hematol*. 2011;86(2):217-220. doi:10.1002/ajh.21917
75. Kearon C. Natural history of venous thromboembolism. *Circulation*. 2003;107(23 Suppl 1):I22-I30. doi:10.1161/01.CIR.0000078464.82671.78
76. Kearon C, Hirsh J. Management of anticoagulation before and after elective surgery. *N Engl J Med*. 1997;336(21):1506-1511. doi:10.1056/NEJM199705223362107
77. Comes RF, Mismetti P, Afshari A; ESA VTE Guidelines Task Force. European guidelines on perioperative venous thromboembolism prophylaxis: Inferior vena cava filters. *Eur J Anaesthesiol*. 2018;35(2):108-111. doi:10.1097/EJA.0000000000000730
78. Schulman S, Svenungsson E, Granqvist S. Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy. Duration of Anticoagulation Study Group. *Am J Med*. 1998;104(4):332-338. doi:10.1016/s0002-9343(98)00060-6
79. Kearon C, Gent M, Hirsh J, et al. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism [published correction appears in *N Engl J Med* 1999 Jul 22;341(4):298]. *N Engl J Med*. 1999;340(12):901-907. doi:10.1056/NEJM199903253401201
80. Segal JB, Brotman DJ, Necochea AJ, et al. Predictive value of factor V Leiden and prothrombin G20210A in adults with venous thromboembolism and in family members of those with a mutation: a systematic review. *JAMA*. 2009;301(23):2472-2485. doi:10.1001/jama.2009.853
81. Lijfering WM, Brouwer JL, Veeger NJ, et al. Selective testing for thrombophilia in patients with first venous thrombosis: results from a retrospective family cohort study on absolute thrombotic risk for currently known thrombophilic defects in 2479 relatives. *Blood*. 2009;113(21):5314-5322. doi:10.1182/blood-2008-10-184879
82. Mulder FI, Candeloro M, Kamphuisen PW, et al. The Khorana score for prediction of venous thromboembolism in cancer patients: a systematic review and meta-analysis. *Haematologica*. 2019;104(6):1277-1287. doi:10.3324/haematol.2018.209114
83. Murin S, Romano PS, White RH. Comparison of outcomes after hospitalization for deep venous thrombosis or pulmonary embolism. *Thromb Haemost*. 2002;88(3):407-414.

84. Witt DM, Nieuwlaat R, Clark NP, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: optimal management of anticoagulation therapy. *Blood Adv.* 2018;2(22):3257-3291. doi:10.1182/bloodadvances.2018024893
85. Baumgartner C, de Kouchkovsky I, Whitaker E, Fang MC. Periprocedural Bridging in Patients with Venous Thromboembolism: A Systematic Review. *Am J Med.* 2019;132(6):722-732.e7. doi:10.1016/j.amjmed.2019.01.004